• downstream
  • It is also reported in this study that a 2-oxoglutarate-dependent dioxygenase-like gene, a cytochrome P450 monooxygenase-like gene, a short-chain dehydrogenase/reductase-like gene, and an α-mannosidase-like gene at the 3' location downstream of PaFS which are responsible for converting fusicocca-2,10(14)-diene into fusicoccin. (wikipedia.org)
  • farnesol
  • Instead, apomine cytotoxicity was prevented by the addition of phosphatidylcholine, which is similar to the previously reported ability of phosphatidylcholine to overcome the cytotoxicity of farnesol, whereas phosphatidylcholine had no effect on down-regulation of HMG-CoA reductase by apomine. (ox.ac.uk)
  • synergistic
  • We conclude that the synergistic drug interaction results from an enhancement by apomine of the effects of lovastatin, mediated by down-regulation of HMG-CoA reductase by apomine. (ox.ac.uk)
  • Competitive
  • These findings raised the possibility that apomine, independent from its own cytotoxic effects, could enhance the antitumor effects of the competitive HMG-CoA reductase inhibitor lovastatin via down-regulating HMG-CoA reductase. (ox.ac.uk)
  • respectively
  • Two enzymes, one dioxygenase and PAPT, are in charge of catalyzing a hydroxylation at the 3-position of fusicocca-2,10(14)-diene-8β,16-diol and prenylation of the hydroxyl group of glucose in fusicoccin P, respectively. (wikipedia.org)
  • effects
  • Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. (ox.ac.uk)
  • domains
  • HMG-CoA reductase is anchored in the membrane of the endoplasmic reticulum, and was long regarded as having seven transmembrane domains, with the active site located in a long carboxyl terminal domain in the cytosol. (wikipedia.org)
  • growth
  • Additional work, including structure-activity relationship studies, identified the human 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor itavastatin as a potent inhibitor of C. parvum growth (50% inhibitory concentration [IC 50 ] = 0.62 μM). (pubmedcentralcanada.ca)